» Articles » PMID: 16685022

High-level Expression of Matrix-associated Transforming Growth Factor-beta1 in Benign Airway Stenosis

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2006 May 11
PMID 16685022
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Study Objectives: Acquired tracheal and subglottic stenosis frequently leads to severe airway narrowing, which requires repeated interventions, such as dilatation, laser resection, stent implantation, or surgery. To get a more detailed insight into the pathogenesis of this condition, we investigated the expression of profibrotic cytokines and the proliferation of the airway wall in benign human airway stenoses.

Methods: Specimens from patients with subglottic and tracheal stenosis and stent-related stenoses were obtained (n = 20) for reverse transcription (RT) polymerase chain reaction (PCR) analysis and immunohistochemistry testing.

Results: Transforming growth factor (TGF)-beta1 messenger RNA expression was significantly increased in biopsy specimens from stent-related stenoses compared to nonstenotic control sections. In contrast, TGF-beta3 and interleukin-1beta showed no such differences in messenger RNA expression. Immunohistochemistry revealed a strong matrix-associated, subepithelial expression of TGF-beta1 in tracheal stenosis. Proliferating Ki-67-positive cells were mainly localized in the basal epithelial layer. Only 2 of 16 patients with tracheal stenoses and 3 of 4 patients with stent-related stenoses showed a weak expression of Ki-67-positive cells in the subepithelium. Furthermore, TGF-beta1 dose-dependently enhanced the proliferation of human lung fibroblasts in vitro, even in the presence of mitomycin-C.

Conclusion: While a weak subepithelial proliferation occurs in stent-related stenoses, the dominant factor in late stages of untreated tracheal stenoses seems to be the high-level expression of TGF-beta1 and the deposition of extracellular matrix.

Citing Articles

Airway stenosis: classification, pathogenesis, and clinical management.

Zhao P, Jiang Z, Li X, Ainiwaer M, Li L, Wang D MedComm (2020). 2025; 6(2):e70076.

PMID: 39866837 PMC: 11769711. DOI: 10.1002/mco2.70076.


Identifying Molecular Pathophysiology and Potential Therapeutic Options in Iatrogenic Tracheal Stenosis.

Martins R, Weber J, Johnson B, Luo J, Poulikidis K, Latif M Biomedicines. 2024; 12(6).

PMID: 38927530 PMC: 11201234. DOI: 10.3390/biomedicines12061323.


miR-34c-5p inhibited fibroblast proliferation, differentiation and epithelial-mesenchymal transition in benign airway stenosis via MDMX/p53 pathway.

Wei J, Chen Y, Feng T, Wei Y, Yang C, Zhang C Funct Integr Genomics. 2024; 24(2):37.

PMID: 38374244 PMC: 10876495. DOI: 10.1007/s10142-024-01317-y.


Biocompatibility and sub-chronic toxicity studies of phlorotannin/polycaprolactone coated trachea tube for advancing medical device applications.

Kim T, Heo S, Oh G, Park W, Jung W Sci Rep. 2024; 14(1):3945.

PMID: 38365854 PMC: 10873353. DOI: 10.1038/s41598-024-54684-8.


Differential expression of miRNAs revealed by small RNA sequencing in traumatic tracheal stenosis.

Li W, Wei J, Huang P, Wei Y, Chang L, Liu G Front Genet. 2024; 14:1291488.

PMID: 38259609 PMC: 10800880. DOI: 10.3389/fgene.2023.1291488.